Reducing depressive symptomatology with a smartphone app: study protocol for a randomized, placebo-controlled trial
Abstract Background Depression has become one of the leading contributors to the global disease burden. Evidence-based treatments for depression are available, but access to them is still limited in some instances. As technology has become more integrated into mental health care, computerized cognit...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-05-01
|
| Series: | Trials |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13063-017-1960-1 |
| _version_ | 1818536043673026560 |
|---|---|
| author | Cezar Giosan Oana Cobeanu Cristina Mogoaşe Aurora Szentagotai Vlad Mureşan Rareș Boian |
| author_facet | Cezar Giosan Oana Cobeanu Cristina Mogoaşe Aurora Szentagotai Vlad Mureşan Rareș Boian |
| author_sort | Cezar Giosan |
| collection | DOAJ |
| description | Abstract Background Depression has become one of the leading contributors to the global disease burden. Evidence-based treatments for depression are available, but access to them is still limited in some instances. As technology has become more integrated into mental health care, computerized cognitive behavioral therapy (CBT) protocols have become available and have been recently transposed to mobile environments (e.g., smartphones) in the form of “apps.” Preliminary research on some depression apps has shown promising results in reducing subthreshold or mild to moderate depressive symptoms. However, this small number of studies reports a low statistical power and they have not yet been replicated. Moreover, none of them included an active placebo comparison group. This is problematic, as a “digital placebo effect” may explain some of the positive effects documented until now. The aim of this study is to test a newly developed mobile app firmly grounded in the CBT theory of depression to determine whether this app is clinically useful in decreasing moderate depressive symptoms when compared with an active placebo. Additionally, we are interested in the app’s effect on emotional wellbeing and depressogenic cognitions. Methods/design Romanian-speaking adults (18 years and older) with access to a computer and the Internet and owning a smartphone are included in the study. A randomized, three-arm clinical trial is being conducted (i.e., active intervention, placebo intervention and delayed intervention). Two hundred and twenty participants with moderate depressive symptoms (i.e., obtaining scores >9 and ≤16 on the Patient Health Questionnaire, PHQ-9) will be randomized to the three conditions. Participants undergoing therapy, presenting serious mental health problems, or legal or health issues that would prevent them from using the app, as well as participants reporting suicidal ideation are excluded. Participants randomized to the active and placebo interventions will use the smartphone app for 6 weeks. A short therapist check-in via phone will take place every week. Participants in the delayed-intervention condition will be given access to the app after 6 weeks from randomization. The primary outcome is the level of depressive symptomatology. The intervention delivered through the app to the active condition includes psychoeducational materials and exercises based on CBT for depression, while the placebo intervention uses a sham version of the app (i.e., similar structure of courses and exercises). Discussion To our knowledge, this study protocol is the first to test the efficacy of a smartphone app for depressive symptomatology in the form of a randomized controlled trial (RCT) that includes an active placebo condition. As such, this can substantially add to the body of evidence supporting the use of apps designed to decrease depression. Trial registration ClinicalTrials.gov, identifier: NCT03060200 . Registered on 1 February 2017. The first participant was enrolled on 17 February 2017. |
| first_indexed | 2024-12-11T18:32:54Z |
| format | Article |
| id | doaj.art-d049aa627ada4f47a1b11174b8b1c834 |
| institution | Directory Open Access Journal |
| issn | 1745-6215 |
| language | English |
| last_indexed | 2024-12-11T18:32:54Z |
| publishDate | 2017-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Trials |
| spelling | doaj.art-d049aa627ada4f47a1b11174b8b1c8342022-12-22T00:54:51ZengBMCTrials1745-62152017-05-0118111210.1186/s13063-017-1960-1Reducing depressive symptomatology with a smartphone app: study protocol for a randomized, placebo-controlled trialCezar Giosan0Oana Cobeanu1Cristina Mogoaşe2Aurora Szentagotai3Vlad Mureşan4Rareș Boian5Department of Clinical Psychology and Psychotherapy, Babeș-Bolyai UniversityDepartment of Clinical Psychology and Psychotherapy, Babeș-Bolyai UniversityDepartment of Clinical Psychology and Psychotherapy, Babeș-Bolyai UniversityDepartment of Clinical Psychology and Psychotherapy, Babeș-Bolyai UniversityDepartment of Clinical Psychology and Psychotherapy, Babeș-Bolyai UniversityDepartment of Clinical Psychology and Psychotherapy, Babeș-Bolyai UniversityAbstract Background Depression has become one of the leading contributors to the global disease burden. Evidence-based treatments for depression are available, but access to them is still limited in some instances. As technology has become more integrated into mental health care, computerized cognitive behavioral therapy (CBT) protocols have become available and have been recently transposed to mobile environments (e.g., smartphones) in the form of “apps.” Preliminary research on some depression apps has shown promising results in reducing subthreshold or mild to moderate depressive symptoms. However, this small number of studies reports a low statistical power and they have not yet been replicated. Moreover, none of them included an active placebo comparison group. This is problematic, as a “digital placebo effect” may explain some of the positive effects documented until now. The aim of this study is to test a newly developed mobile app firmly grounded in the CBT theory of depression to determine whether this app is clinically useful in decreasing moderate depressive symptoms when compared with an active placebo. Additionally, we are interested in the app’s effect on emotional wellbeing and depressogenic cognitions. Methods/design Romanian-speaking adults (18 years and older) with access to a computer and the Internet and owning a smartphone are included in the study. A randomized, three-arm clinical trial is being conducted (i.e., active intervention, placebo intervention and delayed intervention). Two hundred and twenty participants with moderate depressive symptoms (i.e., obtaining scores >9 and ≤16 on the Patient Health Questionnaire, PHQ-9) will be randomized to the three conditions. Participants undergoing therapy, presenting serious mental health problems, or legal or health issues that would prevent them from using the app, as well as participants reporting suicidal ideation are excluded. Participants randomized to the active and placebo interventions will use the smartphone app for 6 weeks. A short therapist check-in via phone will take place every week. Participants in the delayed-intervention condition will be given access to the app after 6 weeks from randomization. The primary outcome is the level of depressive symptomatology. The intervention delivered through the app to the active condition includes psychoeducational materials and exercises based on CBT for depression, while the placebo intervention uses a sham version of the app (i.e., similar structure of courses and exercises). Discussion To our knowledge, this study protocol is the first to test the efficacy of a smartphone app for depressive symptomatology in the form of a randomized controlled trial (RCT) that includes an active placebo condition. As such, this can substantially add to the body of evidence supporting the use of apps designed to decrease depression. Trial registration ClinicalTrials.gov, identifier: NCT03060200 . Registered on 1 February 2017. The first participant was enrolled on 17 February 2017.http://link.springer.com/article/10.1186/s13063-017-1960-1DepressionProtocolRandomized trialPlaceboCBTSmartphone app |
| spellingShingle | Cezar Giosan Oana Cobeanu Cristina Mogoaşe Aurora Szentagotai Vlad Mureşan Rareș Boian Reducing depressive symptomatology with a smartphone app: study protocol for a randomized, placebo-controlled trial Trials Depression Protocol Randomized trial Placebo CBT Smartphone app |
| title | Reducing depressive symptomatology with a smartphone app: study protocol for a randomized, placebo-controlled trial |
| title_full | Reducing depressive symptomatology with a smartphone app: study protocol for a randomized, placebo-controlled trial |
| title_fullStr | Reducing depressive symptomatology with a smartphone app: study protocol for a randomized, placebo-controlled trial |
| title_full_unstemmed | Reducing depressive symptomatology with a smartphone app: study protocol for a randomized, placebo-controlled trial |
| title_short | Reducing depressive symptomatology with a smartphone app: study protocol for a randomized, placebo-controlled trial |
| title_sort | reducing depressive symptomatology with a smartphone app study protocol for a randomized placebo controlled trial |
| topic | Depression Protocol Randomized trial Placebo CBT Smartphone app |
| url | http://link.springer.com/article/10.1186/s13063-017-1960-1 |
| work_keys_str_mv | AT cezargiosan reducingdepressivesymptomatologywithasmartphoneappstudyprotocolforarandomizedplacebocontrolledtrial AT oanacobeanu reducingdepressivesymptomatologywithasmartphoneappstudyprotocolforarandomizedplacebocontrolledtrial AT cristinamogoase reducingdepressivesymptomatologywithasmartphoneappstudyprotocolforarandomizedplacebocontrolledtrial AT auroraszentagotai reducingdepressivesymptomatologywithasmartphoneappstudyprotocolforarandomizedplacebocontrolledtrial AT vladmuresan reducingdepressivesymptomatologywithasmartphoneappstudyprotocolforarandomizedplacebocontrolledtrial AT raresboian reducingdepressivesymptomatologywithasmartphoneappstudyprotocolforarandomizedplacebocontrolledtrial |